Abstract
The aim of this study was to improve the dissolution rate of the poorly soluble drug Clofibrate by delivering the drug as a liquisolid compact. Liquisolid compacts were prepared using propylene glycol as solvent, Microcrystalline cellulose as carrier, Starch and Lactose are used as a coating materials. Sodium starch glycolate and Cross carmellose sodium are used as a Super disintigrants. The crystallinity of the newly formulated drug and the interaction between excipients was examined by X-ray powder diffraction and Fourier-transform infrared spectroscopy, respectively. The dissolution studies for the liquisolid formulation and the Conventional tablet were carried out at a pH 6.8 buffer. The results showed no change in the crystallinity of the drug and no interaction between excipients. The dissolution efficiency of Clofibrate at 60 min was increased from 71.02% for plain drug and 81.3% for Conventional Tablet to 100.47% for the liquisolid formulation. The increase in the dissolution rate was also found to be significant compared to the pure drug and Conventional Tablet at pH 6.8 buffer. The liquisolid technique appears to be a promising approach for improving the dissolution of poorly soluble drugs like Clofibrate.
Highlights
The progress in treatment of diseases has been evident with the upsurge in development of new drugs
For F1–F4 formulations varying concentrations of microcrystalline cellulose is used as a Carrier material, Silica and Starch as a coating material and sodium starch glycol ate is super disintigrant
Clofibrate tablets were prepared by liquisolid technique with different concentrations of Carrier and Coating materials
Summary
The progress in treatment of diseases has been evident with the upsurge in development of new drugs. An estimated 40% of these drugs are poorly water soluble. The enhancement of oral bioavailability of such poorly water soluble drugs remains one of the most challenging aspects of drug development. The development of Liquisolid Compact Technology as a practically viable method to enhance bioavailability of poorly water-soluble drugs overcome the limitations of previous approaches such as salt formation, solubilisation by co solvents, and particle size reduction and other methods. Much of the research that has been reported on Liquisolid Compact technologies involves drugs that are poorly water-soluble and highly permeable to biological membranes as with these drugs dissolution is the rate limiting step to absorption. Liquisolid Compact technologies are promising for improving the oral absorption and bioavailability of BCS Class II drugs [1]. The Bio pharmaceutics Classification System (BCS)[2]: According to the BCS, drugs are classified as follows: www.ssjournals.com
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Biomedical and Advance Research
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
